ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Taken together, the above-mentioned multiple studies suggest that the degradation of BCR-ABL is a potential strategy for the treatment of BCR-ABL-driven chronic myelogenous leukemia.